Madrigal Pharmaceuticals (MDGL) director sale notice: 1,183 shares after RSU vest

Rhea-AI Filing Summary

Madrigal Pharmaceuticals filed a Form 144 disclosing the proposed sale of 1,183 shares of Common Stock in connection with a Restricted Stock Unit grant that vested on 03/02/2026. The filing also reports a prior sale by a 10b5-1 plan of 4,173 shares on 12/02/2025 for $2,413,416.57.

Insights

Securities Compliance Counsel

Routine Form 144 notice tied to RSU vesting and past 10b5-1 sales.

The filing lists a proposed sale of 1,183 shares following a Restricted Stock Unit grant that vested on 03/02/2026. It also documents a prior 10b5-1 plan sale of 4,173 shares on 12/02/2025 for $2,413,416.57.

These items are procedural disclosures required when selling restricted or control securities. Cash‑flow treatment and specific broker or timing details are not included in the excerpt; subsequent filings may provide settlement or execution details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	1183	511056	22939969	03/02/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2026	Restricted Stock Unit Grant	Issuer			1183	03/02/2026	Vesting of Restricted Stock Units

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mardi Dier 10b5-1 Plan c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	12/02/2025	4173	2413416.57

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Madrigal Pharmaceuticals' (MDGL) Form 144 disclose?

The Form 144 discloses a proposed sale of 1,183 shares of common stock tied to a restricted stock unit grant that vested on 03/02/2026. It also reports a prior 10b5-1 sale of 4,173 shares on 12/02/2025 for $2,413,416.57.

Who executed the prior sale listed in the MDGL filing?

The prior sale was executed by a 10b5-1 plan associated with Mardi Dier on 12/02/2025, disposing of 4,173 shares for $2,413,416.57. The filing names the plan and shows the aggregate proceeds.

Why does vesting appear in the MDGL Form 144?

Vesting appears because the proposed sale of 1,183 shares is linked to a Restricted Stock Unit grant that vested on 03/02/2026. The filing ties the sale authorization to the occurrence of that vesting event.

Does the Form 144 state when the 1,183 shares will be sold?

The Form 144 states the proposed sale amount of 1,183 shares and the vesting date of 03/02/2026. It does not provide exact execution timing or broker details for the sale in the provided excerpt.

How much cash was reported from the December 2025 sale in the MDGL filing?

The filing reports aggregate proceeds of $2,413,416.57 from the December 12/02/2025 sale of 4,173 shares executed by the 10b5-1 plan associated with Mardi Dier.